Description: Cyxone AB (publ), a clinical stage biotech company, develops disease modifying therapies for autoimmune and autoinflammatory diseases. Its product pipeline comprises Rabeximod, which is in phase II clinical development for the treatment of rheumatoid arthritis; and T20K for the treatment of multiple sclerosis and is in phase I trial. The company was founded in 2015 and is headquartered in Malmö, Sweden.
Home Page: www.cyxone.com
Hylle Boulevard 34
Malmö,
215 32
Sweden
Phone:
46 7 08 88 21 72
Officers
| Name | Title |
|---|---|
| Dr. Kjell G. Stenberg Ph.D. | Chief Executive Officer |
| Mr. Henrik Hang | Interim Chief Financial Officer |
| Ms. Malin Lindskog | Chief Financial Officer - On Leave |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.0292 |
| Price-to-Sales TTM: | 0.167 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 3 |